Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Gynecol Oncol. 2018 Oct 23;151(3):428–432. doi: 10.1016/j.ygyno.2018.10.017

Table 1:

Demographic and clinical characteristics. BMI=Body mass index, VUS=Variant of unknown significance, R0=no gross residual disease, NOS=not otherwise specified.

N (%)

N=226
Age, median, years (range) 62 (23–88)

BMI, median, kg/m2 (range) 27.1 (17.1–66.8)

Race/Ethnicity
Hispanic or Latino 22 (9.8)
Not Hispanic or Latino 201 (88.9)
Unknown/not reported 3 (1.3)

Known 223 (98.7)
 American Indian/Alaska native 2 (0.9)
 African American/Black 14 (6.3)
 Asian 8 (3.6)
 Caucasian/White 199 (89.2)
Unknown/not reported 3 (1.3)

CA125, median, U/mL (range) 502.6 (10.9–12,472)

Primary disease site
Fallopian tube 9 (4.0)
Ovary 194 (85.8)
Peritoneum 23 (10.2)

Stage
IIA 1 (0.5)
IIB 14 (6.2)
IIIA1 2 (0.9)
IIIA2 3 (1.3)
IIIB 4 (1.8)
IIIC 172 (76.1)
IVA 12 (5.3)
IVB 18 (7.9)

Histology
Serous 194 (85.8)
Endometrioid 4 (1.8)
Clear cell 8 (3.6)
Adenocarcinoma NOS 1 (0.4)
Mixed 12 (5.3)
Carcinosarcoma 7 (3.1)

Residual disease
R0 167 (80.3)
<1cm 20 (9.6)
≥1cm 21 (10.1)